← Leaderboards
Dan H. Barouch
Fred Hutchinson Cancer Center
$218,203,090
Attributed
$591,073,673
Total exposure
39
Grants
31
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $165.8M · FY2005–25$200M$150M$100M$50M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$727,236,348 · 45
By mechanism
UM1$509,465,377 · 5
U19$169,058,088 · 16
R01$25,043,059 · 8
U01$12,682,580 · 2
P01$9,151,180 · 5
P51$878,444 · 7
Top collaborators
- Lawrence Corey19 shared
- Glenda E Gray19 shared
- Georgia D Tomaras19 shared
- John W Mellors10 shared
- Boris Dominik Juelg6 shared
- Louis J. Picker6 shared
- Alex K Shalek6 shared
- Sandhya Vasan6 shared
Most similar at Fred Hutchinson Cancer Center
Same institution · by research overlap
- Peter B. Gilbert$223,972,501
- Yunda Huang$75,372,842
- Georgia D Tomaras$127,423,185
- Holly Janes$70,932,400
- Margaret Juliana McElrath$601,692,649
Others in their field
Top investigators on “Hiv-1”
- Barton F Haynes · Duke University$476,288,740
- Lawrence Corey · Fred Hutchinson Cancer Center$445,419,385
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$294,186,693
- Constance Ann Benson · University Of California, San Diego$272,046,180
- Peter B. Gilbert · Fred Hutchinson Cancer Center$173,010,936
- Daniel R Kuritzkes · Brigham And Women'S Hospital$153,601,785
Research focus
Hiv-1Macaca MulattaVaccinesProgramsImmune ResponseInfectionNeutralizing AntibodyVirusImmuneImmunologicsAntigensRegimenSimian Human Immunodeficiency VirusClinical TrialsNonhuman PrimateImmunogenicityBaseViralResearch PersonnelAntibodiesHiv VaccineVaccine CandidateMediatingCells
Grant awards (194)
HIV Vaccines Clinical Trials Network Leadership and Operations Center$30,396,659
UM1 · FY2025 · AI
I4C 2.0: Immunotherapy for Cure$4,653,643
UM1 · FY2025 · AI · contact PI
Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination$1,505,858
P01 · FY2025 · AI · contact PI
Ad26 Based Therapeutic Vaccines for HIV$1,503,450
U01 · FY2025 · AI · contact PI
Project 2: Analysis of Reservoir Dynamics in SIV-Infected Rhesus Macaques$696,389
P01 · FY2025 · AI · contact PI
NHP Core$327,430
P01 · FY2025 · AI · contact PI
Multi-Omics Correlates of Broadly Neutralizing Antibody Efficacy$276,640
P01 · FY2025 · AI · contact PI
Administrative Core$172,900
P01 · FY2025 · AI · contact PI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$21,949,062
UM1 · FY2024 · AI
I4C 2.0: Immunotherapy for Cure$4,423,055
UM1 · FY2024 · AI · contact PI
LOC: HIV Vaccine Trials Network$2,797,660
UM1 · FY2024 · AI
Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination$1,510,625
P01 · FY2024 · AI · contact PI
Ad26 Based Therapeutic Vaccines for HIV$1,503,450
U01 · FY2024 · AI · contact PI
Single-Cell Analysis of the HIV/SIV Reservoir$821,117
R01 · FY2024 · AI · contact PI
Project 2: Analysis of Reservoir Dynamics in SIV-Infected Rhesus Macaques$696,389
P01 · FY2024 · AI · contact PI
Immunologic Signatures of SARS-CoV-2 Vaccination and Disease$553,087
U01 · FY2024 · CA · contact PI
NHP Core$318,335
P01 · FY2024 · AI · contact PI
Multi-Omics Correlates of Broadly Neutralizing Antibody Efficacy$290,501
P01 · FY2024 · AI · contact PI
Administrative Core$172,901
P01 · FY2024 · AI · contact PI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$38,851,667
UM1 · FY2023 · AI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern$19,404,520
UM1 · FY2023 · AI
I4C 2.0: Immunotherapy for Cure$4,669,992
UM1 · FY2023 · AI · contact PI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$2,683,830
UM1 · FY2023 · AI
Ad26 Based Therapeutic Vaccines for HIV$1,503,450
U01 · FY2023 · AI · contact PI
Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination$1,412,696
P01 · FY2023 · AI · contact PI
Immunologic Signatures of SARS-CoV-2 Vaccination and Disease$897,731
U01 · FY2023 · CA · contact PI
Single-Cell Analysis of the HIV/SIV Reservoir$821,117
R01 · FY2023 · AI · contact PI
Project 2: Analysis of Reservoir Dynamics in SIV-Infected Rhesus Macaques$696,414
P01 · FY2023 · AI · contact PI
Single-Cell Analysis of the HIV/SIV Reservoir$432,250
R01 · FY2023 · AI · contact PI
CoVPN 3001$305,278
UM1 · FY2023 · AI
NHP Core$285,373
P01 · FY2023 · AI · contact PI
Multi-Omics Correlates of Broadly Neutralizing Antibody Efficacy$232,495
P01 · FY2023 · AI · contact PI
Administrative Core$154,996
P01 · FY2023 · AI · contact PI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern$55,953,346
UM1 · FY2022 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$34,194,667
UM1 · FY2022 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$17,943,267
UM1 · FY2022 · AI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$9,754,127
UM1 · FY2022 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$6,272,147
UM1 · FY2022 · AI
CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine LOC$5,663,427
UM1 · FY2022 · AI
CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16$5,323,993
UM1 · FY2022 · AI
I4C 2.0: Immunotherapy for Cure$4,677,761
UM1 · FY2022 · AI · contact PI
CoVPN 3001 GY16 PostMerger LOC$3,879,990
UM1 · FY2022 · AI
Development of Ad26/Env Vaccines for HIV$2,799,999
U19 · FY2022 · AI · contact PI
Ad26 Based Therapeutic Vaccines for HIV$1,503,863
U01 · FY2022 · AI · contact PI
Preclinical Development of Ad26/Env Vaccines for HIV$942,991
U19 · FY2022 · AI · contact PI
Single-Cell Analysis of the HIV/SIV Reservoir$821,117
R01 · FY2022 · AI · contact PI
Immunologic Signatures of SARS-CoV-2 Vaccination and Disease$725,409
U01 · FY2022 · CA · contact PI
Project 2: Analysis of Reservoir Dynamics in SIV-Infected Rhesus Macaques$401,238
P01 · FY2022 · AI · contact PI
Administrative Core$315,829
U19 · FY2022 · AI · contact PI
CoVPN 3502 A Phase 3, Randomized, Double LOC GY16$293,963
UM1 · FY2022 · AI
Core C$229,550
U19 · FY2022 · AI · contact PI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older$61,429,109
UM1 · FY2021 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$43,124,622
UM1 · FY2021 · AI
HIV Vaccines Clinical Trials Network Leadership and Operations Center$40,320,056
UM1 · FY2021 · AI
Consortia for Innovative AIDS Research in Nonhuman Primates$8,268,168
UM1 · FY2021 · AI · contact PI
I4C 2.0: Immunotherapy for Cure$4,904,730
UM1 · FY2021 · AI · contact PI
Development of Ad26/Env Vaccines for HIV$2,800,000
U19 · FY2021 · AI · contact PI
Ad26 Based Therapeutic Vaccines for HIV$1,504,263
U01 · FY2021 · AI · contact PI
Single-Cell Analysis of the HIV/SIV Reservoir$821,117
R01 · FY2021 · AI · contact PI
Impact of the Intestinal Microbiome on HIV/SIV Vaccines$726,413
R01 · FY2021 · OD
Optimization of Broadly Neutralizing Antibodies for HIV Eradication$691,557
R01 · FY2021 · AI · contact PI
Preclinical Development of Ad26/Env Vaccines for HIV$526,823
U19 · FY2021 · AI · contact PI
Administrative Core$371,502
U19 · FY2021 · AI · contact PI
Core C$302,496
U19 · FY2021 · AI · contact PI
Consortia for Innovative AIDS Research in Nonhuman Primates$8,268,211
UM1 · FY2020 · AI · contact PI
Combined Immunologic Approaches to Cure HIV-1$4,630,463
UM1 · FY2020 · AI · contact PI
Development of Ad26/Env Vaccines for HIV$2,799,999
U19 · FY2020 · AI · contact PI
Ad26 Based Therapeutic Vaccines for HIV$1,509,907
U01 · FY2020 · AI · contact PI
Immunologic Signatures of SARS-CoV-2 Vaccination and Disease$1,477,970
U01 · FY2020 · CA · contact PI
Single-Cell Analysis of the HIV/SIV Reservoir$839,867
R01 · FY2020 · AI · contact PI
Preclinical Development of Ad26/Env Vaccines for HIV$796,214
U19 · FY2020 · AI · contact PI
Impact of the Intestinal Microbiome on HIV/SIV Vaccines$788,705
R01 · FY2020 · OD
Core C$753,572
U19 · FY2020 · AI · contact PI
Optimization of Broadly Neutralizing Antibodies for HIV Eradication$696,167
R01 · FY2020 · AI · contact PI
Administrative Core$353,067
U19 · FY2020 · AI · contact PI
Consortia for Innovative AIDS Research in Nonhuman Primates$8,756,867
UM1 · FY2019 · AI · contact PI
Combined Immunologic Approaches to Cure HIV-1$5,042,075
UM1 · FY2019 · AI · contact PI
Development of Ad26/Env Vaccines for HIV$2,799,999
U19 · FY2019 · AI · contact PI
Preclinical Development of Ad26/Env Vaccines for HIV$796,214
U19 · FY2019 · AI · contact PI
Impact of the Intestinal Microbiome on HIV/SIV Vaccines$778,914
R01 · FY2019 · OD
Core C$734,821
U19 · FY2019 · AI · contact PI
Optimization of Broadly Neutralizing Antibodies for HIV Eradication$700,581
R01 · FY2019 · AI · contact PI
Impact of the Intestinal Microbiome on HIV/SIV Vaccines$436,910
R01 · FY2019 · OD
Administrative Core$401,129
U19 · FY2019 · AI · contact PI
Consortia for Innovative AIDS Research in Nonhuman Primates$9,472,469
UM1 · FY2018 · AI · contact PI
Combined Immunologic Approaches to Cure HIV-1$4,630,463
UM1 · FY2018 · AI · contact PI
Development of Ad26/Env Vaccines for HIV$2,800,000
U19 · FY2018 · AI · contact PI
Impact of the Intestinal Microbiome on HIV/SIV Vaccines$789,065
R01 · FY2018 · OD
Optimization of Broadly Neutralizing Antibodies for HIV Eradication$729,269
R01 · FY2018 · AI · contact PI
Preclinical Development of Ad26/Env Vaccines for HIV$672,922
U19 · FY2018 · AI · contact PI
Core C$660,419
U19 · FY2018 · AI · contact PI
Administrative Core$385,912
U19 · FY2018 · AI · contact PI
Scientific Research Support Component C/Non- Human Primates$297,699
UM1 · FY2018 · AI · contact PI
Consortia for Innovative AIDS Research in Nonhuman Primates$11,020,286
UM1 · FY2017 · AI · contact PI
Combined Immunologic Approaches to Cure HIV-1$4,630,463
UM1 · FY2017 · AI · contact PI
Impact of the Intestinal Microbiome on HIV/SIV Vaccines$812,077
R01 · FY2017 · OD
Optimization of Broadly Neutralizing Antibodies for HIV Eradication$748,107
R01 · FY2017 · AI · contact PI
Scientific Research Support Component C/Non- Human Primates$327,518
UM1 · FY2017 · AI · contact PI
Consortia for Innovative AIDS Research in Nonhuman Primates$7,245,181
UM1 · FY2016 · AI · contact PI
Combined Immunologic Approaches to Cure HIV-1$4,630,463
UM1 · FY2016 · AI · contact PI
Novel Ad/MVA and Ad/Protein HIV-1 Vaccines$3,469,355
U19 · FY2016 · AI · contact PI
Scientific Research Support Component C/Non- Human Primates$1,081,255
UM1 · FY2016 · AI · contact PI
Preclinical Evaluation of Novel Ad/MVA and Ad/Protein HIV-1 Vaccines$616,524
U19 · FY2016 · AI · contact PI
Administrative Core$255,207
U19 · FY2016 · AI · contact PI
Consortium for AIDS Vaccine Research in Nonhuman Primates$7,440,564
U19 · FY2015 · AI · contact PI
Novel Ad/MVA and Ad/Protein HIV-1 Vaccines$3,585,085
U19 · FY2015 · AI · contact PI
Preclinical Evaluation of Novel Ad/MVA and Ad/Protein HIV-1 Vaccines$1,117,704
U19 · FY2015 · AI · contact PI
Adenovirus and Poxvirus Mediated Protection Against Mucosal SIV Infection$774,710
U19 · FY2015 · AI · contact PI
Administrative$542,940
U19 · FY2015 · AI · contact PI
Scientific Research Support Component C/Non- Human Primates$480,577
UM1 · FY2015 · AI · contact PI
Administrative Core$254,416
U19 · FY2015 · AI · contact PI
Consortium for AIDS Vaccine Research in Nonhuman Primates$7,888,838
U19 · FY2014 · AI · contact PI
Novel Ad/MVA and Ad/Protein HIV-1 Vaccines$3,647,697
U19 · FY2014 · AI · contact PI
Preclinical Evaluation of Novel Ad/MVA and Ad/Protein HIV-1 Vaccines$900,515
U19 · FY2014 · AI · contact PI
METAGENOMICS OF ENTERIC DISEASE IN SIV-INFECTED AND UNINFECTED MACAQUES$753,932
R01 · FY2014 · OD
Administrative$567,807
U19 · FY2014 · AI · contact PI
Scientific Research Support Component C/Non- Human Primates$439,838
UM1 · FY2014 · AI · contact PI
Adenovirus and Poxvirus Mediated Protection Against Mucosal SIV Infection$337,948
U19 · FY2014 · AI · contact PI
Administrative Core$255,426
U19 · FY2014 · AI · contact PI
Consortium for AIDS Vaccine Research in Nonhuman Primates$6,572,396
U19 · FY2013 · AI · contact PI
Novel Ad/MVA and Ad/Protein HIV-1 Vaccines$3,468,248
U19 · FY2013 · AI · contact PI
Scientific Research Support Component C/Non- Human Primates$2,616,679
UM1 · FY2013 · AI · contact PI
Preclinical Evaluation of Novel Ad/MVA and Ad/Protein HIV-1 Vaccines$1,008,188
U19 · FY2013 · AI · contact PI
Administrative$781,790
U19 · FY2013 · AI · contact PI
Impact of HIV Envelope Conformation on Immunogenicity$753,871
R01 · FY2013 · AI · contact PI
METAGENOMICS OF ENTERIC DISEASE IN SIV-INFECTED AND UNINFECTED MACAQUES$725,744
R01 · FY2013 · OD
Adenovirus and Poxvirus Mediated Protection Against Mucosal SIV Infection$372,251
U19 · FY2013 · AI · contact PI
Administrative Core$240,835
U19 · FY2013 · AI · contact PI
Consortium for AIDS Vaccine Research in Nonhuman Primates$6,991,909
U19 · FY2012 · AI · contact PI
Preclinical Evaluation of Novel Adenovirus Prime-Boost HIV-1 Vaccine$5,220,231
U19 · FY2012 · AI · contact PI
Novel Ad/MVA and Ad/Protein HIV-1 Vaccines$3,865,202
U19 · FY2012 · AI · contact PI
Scientific Research Support Component C/Non- Human Primates$3,756,131
UM1 · FY2012 · AI · contact PI
Novel Heterologous Adenovirus Prime-Boost HIV-1 Vaccine$2,478,197
U19 · FY2012 · AI · contact PI
Preclinical Evaluation of Novel Ad/MVA and Ad/Protein HIV-1 Vaccines$1,034,318
U19 · FY2012 · AI · contact PI
Administrative$844,010
U19 · FY2012 · AI · contact PI
METAGENOMICS OF ENTERIC DISEASE IN SIV-INFECTED AND UNINFECTED MACAQUES$771,951
R01 · FY2012 · OD
Impact of HIV Envelope Conformation on Immunogenicity$766,402
R01 · FY2012 · AI · contact PI
Adenovirus and Poxvirus Mediated Protection Against Mucosal SIV Infection$347,954
U19 · FY2012 · AI · contact PI
Administrative Core$334,933
U19 · FY2012 · AI · contact PI
Administrative Core$255,281
U19 · FY2012 · AI · contact PI
Consortium for AIDS Vaccine Research in Nonhuman Primates$7,013,564
U19 · FY2011 · AI · contact PI
Novel Heterologous Adenovirus Prime-Boost HIV-1 Vaccine$3,549,203
U19 · FY2011 · AI · contact PI
Preclinical Evaluation of Novel Adenovirus Prime-Boost HIV-1 Vaccine$1,132,507
U19 · FY2011 · AI · contact PI
Impact of HIV Envelope Conformation on Immunogenicity$827,465
R01 · FY2011 · AI · contact PI
METAGENOMICS OF ENTERIC DISEASE IN SIV-INFECTED AND UNINFECTED MACAQUES$805,927
R01 · FY2011 · RR
Administrative Core$520,298
U19 · FY2011 · AI · contact PI
Administrative$507,883
U19 · FY2011 · AI · contact PI
Adenovirus and Poxvirus Mediated Protection Against Mucosal SIV Infection$374,702
U19 · FY2011 · AI · contact PI
NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS$68,415
P51 · FY2011 · RR · contact PI
Novel Heterologous Adenovirus Prime-Boost HIV-1 Vaccine$18,931,665
U19 · FY2010 · AI · contact PI
Preclinical Evaluation of Novel Adenovirus Prime-Boost HIV-1 Vaccine$1,691,372
U19 · FY2010 · AI · contact PI
Administrative Core$923,830
U19 · FY2010 · AI · contact PI
Impact of HIV Envelope Conformation on Immunogenicity$841,137
R01 · FY2010 · AI · contact PI
Novel Adenovirus Vaccine Vectors for HIV/SIV$721,067
R01 · FY2010 · AI · contact PI
NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS$65,759
P51 · FY2010 · RR · contact PI
Novel Heterologous Adenovirus Prime-Boost HIV-1 Vaccine$13,123,881
U19 · FY2009 · AI · contact PI
Novel Adenovirus Vector-Based Vaccines for HIV-1$2,969,378
U19 · FY2009 · AI · contact PI
Novel Heterologous Adenovirus Prime-Boost HIV-1 Vaccine$1,620,774
U19 · FY2009 · AI · contact PI
Preclinical Evaluation of Novel Adenovirus Vectors$1,214,370
U19 · FY2009 · AI · contact PI
Preclinical Evaluation of Novel Adenovirus Prime-Boost HIV-1 Vaccine$878,835
U19 · FY2009 · AI · contact PI
Impact of HIV Envelope Conformation on Immunogenicity$858,181
R01 · FY2009 · AI · contact PI
Novel Adenovirus Vaccine Vectors for HIV/SIV$786,648
R01 · FY2009 · AI · contact PI
Administrative Core$489,715
U19 · FY2009 · AI · contact PI
NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS$111,945
P51 · FY2009 · RR · contact PI
Novel Heterologous Adenovirus Prime-Boost HIV-1 Vaccine$4,255,134
U19 · FY2008 · AI · contact PI
Novel Adenovirus Vector-Based Vaccines for HIV-1$2,202,559
U19 · FY2008 · AI · contact PI
Preclinical Evaluation of Novel Adenovirus Vectors$1,222,577
U19 · FY2008 · AI · contact PI
Novel Adenovirus Vaccine Vectors for HIV/SIV$728,351
R01 · FY2008 · AI · contact PI
Preclinical Evaluation of Novel Adenovirus Prime-Boost HIV-1 Vaccine$725,423
U19 · FY2008 · AI · contact PI
Administrative Core$410,686
U19 · FY2008 · AI · contact PI
Augmentation of DNA Vaccine-Elicited Immunity to HIV/SIV$369,208
R01 · FY2008 · AI · contact PI
NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS$237,907
P51 · FY2008 · RR · contact PI
Novel Adenovirus Vector-Based Vaccines for HIV-1$4,058,366
U19 · FY2007 · AI · contact PI
Preclinical Evaluation of Novel Adenovirus Vectors$1,267,414
U19 · FY2007 · AI · contact PI
Novel Adenovirus Vaccine Vectors for HIV/SIV$615,118
R01 · FY2007 · AI · contact PI
Augmentation of DNA Vaccine-Elicited Immunity to HIV/SIV$372,880
R01 · FY2007 · AI · contact PI
NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS$190,552
P51 · FY2007 · RR · contact PI
Novel Adenovirus Vector-Based Vaccines for HIV-1$7,304,539
U19 · FY2006 · AI · contact PI
Preclinical Evaluation of Novel Adenovirus Vectors$728,482
U19 · FY2006 · AI · contact PI
Novel Adenovirus Vaccine Vectors for HIV/SIV$610,684
R01 · FY2006 · AI · contact PI
Augmentation of DNA Vaccine-Elicited Immunity to HIV/SIV$436,290
R01 · FY2006 · AI · contact PI
NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS$134,807
P51 · FY2006 · RR · contact PI
Novel Adenovirus Vector-Based Vaccines for HIV-1$3,296,945
U19 · FY2005 · AI
Preclinical Evaluation of Novel Adenovirus Vectors$626,681
U19 · FY2005 · AI
Augmentation of DNA Vaccine-Elicited Immunity to HIV/SIV$335,267
R01 · FY2005 · AI
Administrative$303,368
U19 · FY2005 · AI
Chimeric Adenovirus Vaccine Vectors for HIV/SIV$255,000
R21 · FY2005 · AI
Cytokine-Augmented DNA Vaccine-Elicited Immunity to HIV$106,583
K08 · FY2005 · AI
NOVEL RECOMBINANT ADENOVIRUS VACCINE VECTORS FOR HIV/SIV IN RHESUS MONKEYS$69,059
P51 · FY2005 · RR
Augmentation of DNA Vaccine-Elicited Immunity to HIV/SIV$508,586
R01 · FY2004 · AI
Chimeric Adenovirus Vaccine Vectors for HIV/SIV$255,000
R21 · FY2004 · AI
Cytokine-Augmented DNA Vaccine-Elicited Immunity to HIV$123,579
K08 · FY2004 · AI
Cytokine-Augmented DNA Vaccine-Elicited Immunity to HIV$108,729
K08 · FY2003 · AI
Cytokine-Augmented DNA Vaccine-Elicited Immunity to HIV$108,729
K08 · FY2002 · AI